Zhi Xiang Jintai: GR1802 injection liquid adolescent seasonal allergic rhinitis indications have been approved for clinical trials.

Zhixiang Jintai announced that the company recently received the approval and issuance of the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration. The company's clinical trial application for GR1802 Injection for adolescent seasonal allergic rhinitis indications was approved. GR1802 Injection is a recombinant human anti-IL-4R monoclonal antibody independently developed by the company, targeting IL-4R. Previously, GR1802 Injection has received clinical trial approval notices for multiple indications, with indications for moderate to severe atopic dermatitis in adults, chronic sinusitis with nasal polyps, chronic spontaneous urticaria, and allergic rhinitis in phase III clinical trials, asthma in phase II clinical trials, and atopic dermatitis in children/adolescents in phase Ib/II clinical trials.